Last updated: September 4, 2026
Tafamidis is Pfizer’s largest growth product outside its COVID-19 portfolio and the leading commercial therapy for transthyretin amyloid cardiomyopathy, or ATTR-CM. Pfizer’s Vyndaqel family revenue increased from approximately $154 million in 2019 to about $3.3 billion in 2023, driven by diagnosis expansion, treatment of wild-type ATTR-CM, and conversion from Vyndaqel to the higher-strength Vyndamax presentation. The market is entering a more competitive phase following FDA approval of acoramidis in 2024 and the potential expansion of RNA-silencing therapies into ATTR-CM.
What is tafamidis and which products contain it?
Tafamidis is a transthyretin stabilizer that binds the thyroxine-binding sites of the transthyretin tetramer. It reduces tetramer dissociation, a rate-limiting step in the formation of amyloid fibrils.
Pfizer commercializes three principal presentations:
| Product |
Active ingredient |
Primary market use |
Regulatory position |
| Vyndaqel |
Tafamidis meglumine |
ATTR-CM and transthyretin familial amyloid polyneuropathy in selected markets |
FDA-approved for ATTR-CM |
| Vyndamax |
Tafamidis free acid |
ATTR-CM |
FDA-approved for ATTR-CM |
| Vyndaqel 20 mg capsules |
Tafamidis meglumine |
Transthyretin familial amyloid polyneuropathy outside the U.S. |
Approved in Europe and other markets |
The U.S. ATTR-CM regimen is four 20 mg Vyndaqel capsules once daily or one 61 mg Vyndamax capsule once daily. The two products deliver equivalent tafamidis free-acid exposure for ATTR-CM, but Vyndamax has a simpler dosing format.
How has Pfizer’s tafamidis revenue changed?
Pfizer’s Vyndaqel family has moved from a specialty orphan product to a multibillion-dollar franchise.
| Fiscal year |
Approximate Vyndaqel-family revenue |
Commercial development |
| 2019 |
$154 million |
U.S. ATTR-CM approval late in the year |
| 2020 |
$1.3 billion |
Initial U.S. launch and rapid specialist adoption |
| 2021 |
$2.0 billion |
Expansion in wild-type ATTR-CM |
| 2022 |
$2.6 billion |
Broader diagnosis and treatment penetration |
| 2023 |
$3.3 billion |
Continued volume growth and Vyndamax conversion |
| 2024 |
Approximately $5 billion-plus |
Strong global demand, with competitive entry beginning |
The 2019-to-2023 revenue increase represents a compound annual growth rate of roughly 116%, although the calculation starts from a partial launch year. From 2020 to 2023, revenue grew at approximately 36% annually.
Pfizer’s reported figures include Vyndaqel, Vyndamax and, where applicable, Vynmac. Currency movements, geographic mix and product-level reporting policies affect year-to-year comparisons. The principal driver has been volume rather than price alone.
Why has tafamidis generated strong market growth?
How large is the ATTR-CM addressable market?
ATTR-CM was historically underdiagnosed because its symptoms overlap with heart failure with preserved ejection fraction, hypertrophic cardiomyopathy and age-related cardiac disease. Improved diagnostic pathways have increased testing among older patients with unexplained ventricular wall thickening, heart failure, carpal tunnel syndrome, spinal stenosis and other extracardiac indicators.
The commercial market has expanded through:
- Greater recognition of wild-type ATTR-CM in older men.
- Increased use of technetium-based bone scintigraphy.
- Wider availability of genetic testing for hereditary ATTR.
- Cardiology and heart-failure screening programs.
- Longer treatment duration after diagnosis.
- Earlier treatment before advanced functional decline.
The pivotal ATTR-ACT trial showed reduced mortality and cardiovascular hospitalizations over 30 months in patients with ATTR-CM receiving tafamidis. Long-term extension data supported continued clinical benefit, although the treatment effect is strongest when therapy begins before severe disease progression.[1,2]
Which segment drives Pfizer’s sales?
Wild-type ATTR-CM is the largest commercial segment in developed markets. It affects predominantly older adults and generally has a larger diagnosed population than hereditary ATTR-CM in North America and Western Europe.
Hereditary ATTR-CM is smaller but more geographically concentrated. Higher prevalence has been reported in Portugal, Sweden, Japan, Brazil and selected regions with founder mutations. The hereditary ATTR polyneuropathy market is commercially relevant outside the United States, where Pfizer competes with RNA-silencing products such as patisiran and vutrisiran.
What is the FDA regulatory status of tafamidis?
The FDA approved tafamidis meglumine and tafamidis free acid on May 3, 2019, for the treatment of cardiomyopathy caused by wild-type or hereditary transthyretin-mediated amyloidosis in adults.[3]
The FDA-approved U.S. indication is ATTR-CM. Tafamidis is not FDA-approved for transthyretin-mediated polyneuropathy, although the drug has that indication in other jurisdictions.
Key FDA milestones include:
| Date |
Event |
| May 2019 |
FDA approval of Vyndaqel and Vyndamax for ATTR-CM |
| 2019 onward |
Orphan-drug commercial protection and U.S. launch |
| 2021-2023 |
Expanded clinical adoption in cardiology and heart-failure practices |
| November 2024 |
FDA approval of acoramidis, creating a direct oral ATTR-CM competitor |
Vyndamax reduced the pill burden from four capsules to one capsule daily. That change supported adherence and made Vyndamax the commercially preferred U.S. presentation.
When does tafamidis lose exclusivity?
Tafamidis has several layers of protection rather than a single loss-of-exclusivity date.
| Protection layer |
Relevance |
| Original composition patents |
Cover the tafamidis chemical entity and related benzoxazole compounds |
| Formulation and dosage patents |
Can cover the 61 mg free-acid capsule and high-dose ATTR-CM administration |
| Method-of-use patents |
Cover treatment of ATTR-CM or transthyretin-mediated disease |
| FDA orphan-drug exclusivity |
Applies to the U.S. ATTR-CM approval for seven years from approval |
| FDA regulatory exclusivity |
May apply separately from patent rights depending on the approval basis |
The seven-year U.S. orphan exclusivity period tied to the 2019 ATTR-CM approval extends into 2026. The original composition patent estate does not provide a simple market-wide end date because later-listed patents may continue to affect specific products, dosage forms or uses.
The practical U.S. generic-entry window depends on:
- Whether a generic applicant challenges Pfizer’s listed patents.
- Whether Pfizer obtains a 30-month stay from a Paragraph IV lawsuit.
- Whether the challenged claims survive litigation.
- Whether FDA orphan exclusivity blocks approval for the relevant indication.
- Whether a generic launches for an unprotected indication or at-risk before final judgment.
What is the Orange Book status of Vyndaqel and Vyndamax?
Vyndaqel and Vyndamax are listed in the FDA Orange Book with patent information submitted by Pfizer. Orange Book patents can cover the active ingredient, dosage form, formulation or approved method of use.
The commercial significance differs by product:
- Vyndaqel has a multi-capsule 20 mg regimen.
- Vyndamax has a single 61 mg capsule regimen.
- A generic tafamidis product could face separate barriers depending on whether it references Vyndaqel, Vyndamax or both.
- A generic applicant may use a Paragraph IV certification to challenge listed patents before expiration.
- A non-infringing label could omit a patented method of use, but that approach may limit commercial value in ATTR-CM.
The main risk is not simply whether the earliest compound patent has expired. Pfizer can preserve product-level protection through formulation, dose and method-of-use claims. Any launch analysis must map each Orange Book-listed patent to the reference product and proposed generic label.[4]
Which companies are challenging or competing with tafamidis?
How does acoramidis compare with tafamidis?
Acoramidis, marketed as Attruby by BridgeBio and Bayer, was FDA-approved in November 2024 for ATTR-CM. It is an oral transthyretin stabilizer and the first directly positioned U.S. competitor to tafamidis in the ATTR-CM indication.
| Factor |
Tafamidis |
Acoramidis |
| Mechanism |
TTR tetramer stabilization |
TTR tetramer stabilization |
| U.S. brand |
Vyndaqel/Vyndamax |
Attruby |
| Dosing |
Once daily |
Twice daily |
| Approval basis |
ATTR-ACT |
ATTRibute-CM |
| Commercial advantage |
Established diagnosis and treatment infrastructure |
New entrant with competitive clinical and pricing positioning |
| Main risk to incumbent |
Patient switching and payer negotiation |
Slower uptake from twice-daily dosing and limited launch history |
Acoramidis could pressure Pfizer through formulary competition, discounts and new-patient share. Tafamidis retains advantages in physician familiarity, long-term exposure, global availability and once-daily dosing.
Could RNA-silencing therapies reduce tafamidis demand?
Patisiran and vutrisiran suppress transthyretin production rather than stabilize circulating tetramers. Both are important competitors in hereditary ATTR polyneuropathy. Their impact on tafamidis depends on the indication.
Vutrisiran generated significant competitive concern after positive ATTR-CM data from the HELIOS-B study. Expansion into cardiomyopathy would give Alnylam a differentiated treatment approach, potentially used alone or in combination with a stabilizer. Combination therapy could expand the market but could also reduce tafamidis monotherapy share.
Ionis and AstraZeneca’s eplontersen is another RNA-targeted therapy with potential relevance to ATTR disease. Its current commercial focus is polyneuropathy, with future cardiomyopathy data determining its competitive scope.
What patent litigation and Paragraph IV risks affect tafamidis?
Publicly visible market risk has historically been lower than for mass-market small molecules because tafamidis addresses a rare disease and its commercial value depends on a narrow, technically complex indication. That profile can delay generic entry even after core composition claims expire.
The principal litigation scenarios are:
- A Paragraph IV challenge to Vyndamax formulation or dosage claims.
- A challenge to Vyndaqel method-of-use patents for ATTR-CM.
- A generic filing that seeks approval for a narrower label.
- Settlement allowing a launch before the latest patent expiration.
- Authorized-generic or licensing arrangements negotiated by Pfizer.
A successful generic would need to establish bioequivalence and meet the relevant labeling requirements. Tafamidis does not have the manufacturing complexity of a biologic, but capsule equivalence, salt/free-acid differences, dosage conversion and indication-specific labeling can create regulatory barriers.
How strong is Pfizer’s tafamidis patent estate?
Pfizer’s strongest commercial protection is the combined product and regulatory estate rather than any single early composition patent.
Patent strengths
- Established active ingredient and pharmaceutical manufacturing know-how.
- U.S. orphan exclusivity through the 2026 period.
- Separate Vyndaqel and Vyndamax product configurations.
- Method-of-use protection linked to ATTR-CM.
- Large clinical evidence base supporting treatment-specific labeling.
- Global patent and regulatory filings across major pharmaceutical markets.
Patent weaknesses
- Tafamidis is a small molecule with potentially accessible synthesis.
- The original chemical composition protection is older than the 2019 U.S. approval.
- Generic manufacturers can target narrow labels.
- Orphan exclusivity does not permanently block competition.
- Acoramidis and RNA-silencing therapies weaken the value of long-term monopoly pricing.
The estate is commercially strong in the near term but less secure after the mid-2020s. Its durability depends on the enforceability of later patents and Pfizer’s ability to defend Vyndamax-specific claims.
What generic launch scenarios exist for tafamidis?
Scenario 1: Delayed generic entry
Pfizer defeats Paragraph IV challenges, and Vyndamax remains protected until the last enforceable patent expires. This is the most favorable scenario for Pfizer.
Scenario 2: Settlement-based entry
Pfizer permits a generic launch before the latest patent expiration in exchange for payment, a supply arrangement or a negotiated entry date. This is common where litigation risk is balanced and the branded market remains commercially attractive.
Scenario 3: At-risk launch
A generic launches before final patent resolution. Pfizer seeks damages and an injunction. The generic accepts substantial litigation exposure in exchange for early market access.
Scenario 4: Indication-limited competition
A generic obtains approval with a label that omits a patented method of use. This could produce limited substitution but would not necessarily replicate Vyndamax’s full ATTR-CM commercial position.
How does geographic coverage affect tafamidis revenue?
The United States is the largest single commercial market because of high drug prices, broad diagnosis capacity and a large population with wild-type ATTR-CM. Japan and Europe are also important, with different reimbursement rules and earlier experience using tafamidis for hereditary ATTR polyneuropathy.
| Region |
Market characteristics |
| United States |
Highest revenue per patient; strong cardiology adoption; significant payer and Medicare exposure |
| Europe |
Country-level reimbursement decisions; established polyneuropathy use |
| Japan |
Significant ATTR awareness and hereditary disease expertise |
| Latin America |
Important hereditary ATTR clusters but lower average pricing |
| Emerging markets |
Lower access and reimbursement; long-term volume opportunity |
International reference pricing can limit Pfizer’s ability to sustain U.S.-level prices globally. Currency changes also affect reported revenue.
What revenue exposure does Pfizer have to tafamidis?
At approximately $3.3 billion in 2023 revenue, Vyndaqel represented a meaningful share of Pfizer’s non-COVID portfolio. At 2024 revenue above $5 billion, the product family became one of Pfizer’s most important growth franchises.
The exposure creates both strategic value and concentration risk:
- Continued diagnosis growth can support revenue expansion.
- Acoramidis can increase payer discounts.
- RNA-silencing therapies can change treatment sequencing.
- U.S. exclusivity loss could reduce price and volume.
- The franchise remains less exposed to biosimilar substitution because tafamidis is a small molecule, not a biologic.
The most likely post-2026 pattern is a gradual decline rather than an immediate collapse, provided Pfizer retains patent protection and physicians continue to favor its once-daily product. Net price erosion could begin before generic entry because insurers will negotiate against new competitors.
What is the commercial outlook for tafamidis?
Tafamidis remains the leading ATTR-CM product through the near term. Revenue growth should moderate as diagnosis penetration rises, acoramidis enters formularies and treatment alternatives expand.
The commercial outlook depends on four variables:
- The rate of ATTR-CM diagnosis.
- Relative payer access for Vyndamax and Attruby.
- Clinical adoption of RNA-silencing therapies in cardiomyopathy.
- The enforceability and timing of Pfizer’s later patent claims.
The strongest growth opportunity is earlier diagnosis and treatment of wild-type ATTR-CM. The largest downside risk is a competitive treatment class that demonstrates superior outcomes, simpler administration or materially lower cost.
Key Takeaways
- Tafamidis is Pfizer’s Vyndaqel and Vyndamax franchise for ATTR-CM.
- Revenue grew from approximately $154 million in 2019 to $3.3 billion in 2023 and above $5 billion in 2024.
- Vyndamax’s once-daily capsule has improved convenience and supported product conversion.
- U.S. orphan exclusivity from the 2019 ATTR-CM approval extends into 2026.
- Patent risk is concentrated in later formulation, dosage and method-of-use claims.
- Acoramidis is the first direct oral U.S. competitor in ATTR-CM.
- Vutrisiran, patisiran and eplontersen create additional class competition through transthyretin suppression.
- Generic entry is likely to be shaped by Paragraph IV litigation, settlement timing and indication-specific labeling.
- Tafamidis has strong near-term commercial protection but faces greater pricing and share pressure after 2026.
FAQs
Is tafamidis a biologic or a small-molecule drug?
Tafamidis is a small-molecule drug. It is manufactured as an oral capsule and is not subject to biosimilar substitution rules.
Is Vyndamax the same drug as Vyndaqel?
Both contain tafamidis. Vyndamax contains tafamidis free acid in a 61 mg capsule, while Vyndaqel contains tafamidis meglumine in four 20 mg capsules for the ATTR-CM regimen.
Does tafamidis treat ATTR polyneuropathy in the United States?
No. The FDA-approved U.S. indication is ATTR-CM. Tafamidis is approved for transthyretin familial amyloid polyneuropathy in several non-U.S. markets.
Will acoramidis replace tafamidis?
Acoramidis is unlikely to replace tafamidis immediately. It will compete for new patients, payer-preferred status and potentially treatment switches, while tafamidis retains greater market maturity and once-daily dosing.
What is the largest long-term risk to tafamidis revenue?
The largest risk is competitive displacement in ATTR-CM by a lower-cost stabilizer or an RNA-silencing therapy with superior outcome data, reinforced by generic or patent-driven price erosion after the U.S. exclusivity period.
References
-
Maurer, M. S., Schwartz, J. H., Gundapaneni, B., Elliott, P. M., Merlini, G., Waddington-Cruz, M., Kristen, A. V., Grogan, M., Witteles, R., Damy, T., Drachman, B. M., Shah, S. J., Hanna, M., Judge, D. P., Barsdorf, A. I., Huber, P., Patterson, T. A., Riley, S., & Rapezzi, C. (2018). Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. New England Journal of Medicine, 379(11), 1007-1016. https://doi.org/10.1056/NEJMoa1805689
-
U.S. Food and Drug Administration. (2019). FDA approves new treatments for heart disease caused by transthyretin-mediated amyloidosis. https://www.fda.gov
-
U.S. Food and Drug Administration. (2024). Drug approval package: Attruby (acoramidis). https://www.fda.gov
-
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
-
Pfizer Inc. (2024). 2023 annual report. https://www.pfizer.com/investor/financial-reports
-
Pfizer Inc. (2025). 2024 annual report. https://www.pfizer.com/investor/financial-reports
-
Alnylam Pharmaceuticals, Inc. (2024). HELIOS-B phase 3 study of vutrisiran in transthyretin-mediated amyloidosis with cardiomyopathy. https://www.alnylam.com
-
BridgeBio Pharma, Inc. (2024). FDA approval of Attruby for adults with cardiomyopathy caused by wild-type or hereditary transthyretin-mediated amyloidosis. https://bridgebio.com
